CSF2 and plasma cell myeloma: Dinutuximab (UnituxinTM, United Therapeutics Corporation, Silver Spring, MD, USA) is an IgG1 human/mouse chimeric Ab produced in mouse myeloma cell line SP2/0 [40], approved by the Food and Drug Administration (FDA) in 2015 for high-risk pediatric neuroblastoma treatment in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis retinoic acid (RA) [21].